medigraphic.com
SPANISH

Revista Mexicana de Pediatría

ISSN 0035-0052 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2004, Number 3

<< Back Next >>

Rev Mex Pediatr 2004; 71 (3)

Combined therapy in the treatment of infants with oxygen dependence

Delgadillo-Avendaño JM, Robledo-Galván AE, Hernández-Rodríguez V, Frías-Vallejo G
Full text How to cite this article

Language: Spanish
References: 11
Page: 123-127
PDF size: 73.52 Kb.


Key words:

Antileukotrienes, oxygen therapy, inflammatory lung disease.

ABSTRACT

Objective. To look for a therapeutic alternative in neonates with oxygen dependence. Material and methods. Sixteen children were studied with an inflammatory lung disease dependent of oxygen. They were treated with antileukotrienes every 24 hours and steroids inhalation twice a day. The presence of bonchopulmonary secretions, bronchospasmus and the oxygen necessity were valued. The number of leukocytes and the percentage of eosinophiles were study at the beginning and when the treatment finished. Results. During the treatment there was a diminish in percentage of eosinophiles and leukocytes, according to the reduction of oxygen dependence. The secretions diminished in 15/16 (0.94) and the bonchospasmus in 13/16 (0.81). When the study conclude 15/16 of the infants didn’t depend on oxygen (0.94). The oxygen dependence was for a mean of 64 days. Conclusions. The combined therapy of antileukotriene and inhaled steroids seem to be a reasonable alternative to treat infants with chronicle pulmonary diseases.


REFERENCES

  1. Ress PJ, Dudley F. Oxygen therapy in chronic lung disease. BMJ 1998; 317: 871-74.

  2. Hernández RL, Téllez ZJF, Salinas RV, Zapata PJA. Factores de riesgo para el desarrollo de displasia broncopulmonar neonatal en el Instituto Nacional de Perinatología. Bol Med Hosp Infant Mex 2002; 59: 461-9.

  3. Northway WH, Rosan R, Porter D. Pulmonary disease following respiratory therapy or hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357-64.

  4. Northway WH, Moss RB, Carlisle KB, Parker BR, Popp RL. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990; 323: 1793-9.

  5. Crapo JD, Allen GH, Michael PS, Musson RA. Pulmonary immunobiology and inflammation in pulmonary diseases. Am J Respir Crit Care Med 2002; 162: 1983-6.

  6. Penrose JF. Physiology of lipid mediators-prostaglandins; leukotrienes and lipoxinas-and their role in inflammation. Uptodate topic; review. www.uptodate.com

  7. Jackson RM. Pulmonary oxygen toxicity. Chest 1985; 88(6): 900-6.

  8. Griffith DE, Garcia JG, James HL, Callaham KS, Iriana S, Holiday D. Hiperoxic exposure in humans. Chest 1992; 101(2): 392-7.

  9. Fine A, Janssen-Heininger Y, Soultanakis RP et al. Apoptosis in lung pathophysiology. Lung Cell Mol Physiol 2000; 279: 423-7.

  10. Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163: 226-233.

  11. Howarth P. Small airway inflammation and asthma. Int J Clin Pract 1998; 96(Suppl): 15-22.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Mex Pediatr. 2004;71